AbbVie Inc. $ABBV Shares Sold by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 32.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,906 shares of the company’s stock after selling 5,131 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in AbbVie were worth $2,525,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after purchasing an additional 448,554 shares in the last quarter. Geode Capital Management LLC grew its holdings in AbbVie by 2.4% in the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after purchasing an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after buying an additional 1,517,222 shares in the last quarter. Norges Bank acquired a new position in shares of AbbVie during the 2nd quarter worth $4,288,200,000. Finally, Raymond James Financial Inc. raised its stake in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

AbbVie stock opened at $224.13 on Friday. The firm’s fifty day moving average price is $224.01 and its 200 day moving average price is $221.70. The company has a market capitalization of $396.12 billion, a price-to-earnings ratio of 94.97, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.1%. AbbVie’s dividend payout ratio is presently 293.22%.

Analyst Ratings Changes

ABBV has been the topic of a number of research reports. Scotiabank initiated coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Berenberg Bank set a $275.00 price target on AbbVie in a research note on Tuesday, January 20th. Raymond James Financial set a $256.00 target price on AbbVie in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $252.79.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Board declared a quarterly cash dividend of $1.73 per share (annualized yield ~3.1%), payable May 15 to holders of record April 15 — supports income investor demand and underscores management’s commitment to returning cash. AbbVie Declares Quarterly Dividend
• Positive Sentiment: Investment write-ups highlight AbbVie as a Dividend King and a multi-area biotech with durable cash flows — narrative that attracts dividend-focused buyers. 2 Dividend Stocks to Hold for the Next 5 Years
• Positive Sentiment: VOLITE skin-quality trial reported completion updates — clinical progress in aesthetics could help diversify revenue beyond core immunology franchises. AbbVie’s VOLITE Skin Quality Trial Completion
• Positive Sentiment: Coverage pieces suggest AbbVie’s post-Humira pipeline progress (Tremfya and others) could prompt renewed investor interest if share gains and new launches continue. This is a potential catalyst for medium-term revenue growth. Should AbbVie’s Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: AbbVie launched a branded podcast, “The Persistence Lab,” to highlight innovation — helpful for PR/brand but unlikely to move fundamentals quickly. AbbVie heads to ‘The Persistence Lab’
• Neutral Sentiment: Analyst commentary and aggregator pieces (Zacks, Yahoo Top Analyst Reports) continue to highlight AbbVie following its earnings beat — supportive background but mixed across firms. The Zacks Analyst Blog
• Negative Sentiment: Evercore trimmed its price target slightly and warned that while Tremfya is gaining share, future earnings growth could be limited — a caution that may restrain upgrades and cap near-term upside. Evercore Notes Tremfya Gains Market Share

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.